Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Aditxt Temettü

Temettü kriter kontrolleri 0/6

Aditxt şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$321.51
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Aditxt gains on regaining compliance with Nasdaq listing requirements

Sep 29

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Sep 13

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Jul 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ADTX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ADTX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Aditxt Piyasaya Karşı Temettü Getirisi

ADTX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ADTX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (ADTX) (3 yıla kadar)	n/a

Önemli Temettü: ADTX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ADTX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ADTX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ADTX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Aditxt Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. has filed a Follow-on Equity Offering in the amount of $1.197058 million.

Aditxt, Inc. announced that it has received $0.5 million in funding

Aditxt, Inc., Annual General Meeting, Aug 07, 2024

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. announced that it expects to receive $4.2 million in funding

Aditxt, Inc. announced delayed annual 10-K filing

Aditxt, Inc. announced that it has received $6.000003 million in funding

Aditxt Regains Compliance with Nasdaq Stockholders' Equity Requirement

Aditxt, Inc. (NasdaqCM:ADTX) entered into an agreement and plan of merger to acquire Evofem Biosciences, Inc. (OTCPK:EVFM) from shareholders.

Third quarter 2023 earnings released: US$47.13 loss per share (vs US$211 loss in 3Q 2022)

Aditxt, Inc. Announces Board Changes

Nasdaq Hearings Panel Grants Aditxt an Exception through December 26, 2023 to Allow Aditxt to Complete its Plan to Demonstrate Compliance with the Equity Rule

Aditxt Receives Written Notice from Nasdaq

Aditxt, Inc. announced that it has received $10 million in funding

Aditxt, Inc. announced that it expects to receive $10 million in funding

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$6.42 loss in 2Q 2022)

Insufficient new directors

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

Aditxt, Inc., Annual General Meeting, Aug 16, 2023

Aditxt Receives Notice from Nasdaq Due to Non-Compliance with Minimum Stockholders Equity Requirement

Aditxt, Inc. Announces Development and Publication of Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection

Aditxt Regains Compliance with Nasdaq Listing Requirements

Aditxt gains on regaining compliance with Nasdaq listing requirements

Aditxt, Inc. has completed a Follow-on Equity Offering.

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Aditxt, Inc., Annual General Meeting, Jun 24, 2022

Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron

Aditxt Provides Update on AditxtReprogramming’s Apoptotic DNA Immunotherapy Therapeutic Platform

High number of new directors

Aditx Therapeutics, Inc. Announces Enhancements to Its Aditxtscore for COVID-19

Aditxt adds Lauren Chung to board of directors

Co-Founder exercised options to buy US$60k worth of stock.

Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services

New 90-day high: US$4.10

ADiTx Therapeutics, Inc. Appoints Dolly B. Tyan as Senior Vice President of Clinical Development - Transplantation

Aditx Therapeutics, Inc. Announces the Operational Launch of the AditxtScore™ Immune Monitoring Platform

New 90-day high: US$2.61

Aditxt Signs Distribution Agreement with Todos Medical Ltd. for Aditxtscore™ for Covid-19 Immune Monitoring Service

Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring

New 90-day high: US$2.39

We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth

Aditx Therapeutics, Inc. Appoints Anthony Voorhies as Head of Business Development for AditxtScore

Aditx Therapeutics, Inc. Secures CLIA Certification for AditxtScore™ Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test

ADiTx Therapeutics, Inc. has completed a Composite Units Offering in the amount of $9.6 million.

ADiTx Therapeutics, Inc. has completed an IPO in the amount of $11.040012 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin